Literature DB >> 15269355

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells.

Robert Drillien1, Danièle Spehner1, Daniel Hanau1.   

Abstract

Modified vaccinia virus Ankara (MVA) is a highly attenuated strain known to be an effective vaccine vector. Here it is demonstrated that MVA, unlike standard vaccinia virus (VACV) strains, activates monocyte-derived human dendritic cells (DCs) as testified by an increase in surface co-stimulatory molecules and the secretion of pro-inflammatory cytokines. Inhibition of virus gene expression by subjecting MVA to UV light or heat treatment did not alter its ability to activate DCs. On the other hand, standard VACV strains activated DCs if virus gene expression was prevented by prior UV light or heat treatment. These results suggest that MVA or standard VACV particles are responsible for DC activation but, in the case of standard VACV strains, virus gene expression prevents activation. Additional experiments showed that DCs were activated by MVA-infected HeLa cells and, under these conditions, could induce secretion of gamma interferon from T lymphocytes more efficiently than if a replication-competent VACV strain was employed. These data provide one explanation for the remarkable immune-stimulating capacity of MVA in the absence of virus multiplication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269355     DOI: 10.1099/vir.0.79998-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  31 in total

1.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

Authors:  Yongxue Yao; Ping Li; Pratibha Singh; Allison T Thiele; David S Wilkes; Gourapura J Renukaradhya; Randy R Brutkiewicz; Jeffrey B Travers; Gary D Luker; Soon-Cheol Hong; Janice S Blum; Cheong-Hee Chang
Journal:  Cell Immunol       Date:  2007-08-02       Impact factor: 4.868

3.  Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.

Authors:  Samantha Brandler; Alice Lepelley; Marion Desdouits; Florence Guivel-Benhassine; Pierre-Emmanuel Ceccaldi; Yves Lévy; Olivier Schwartz; Arnaud Moris
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

4.  Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation.

Authors:  Nicole L Yates; Martha A Alexander-Miller
Journal:  Virology       Date:  2006-10-20       Impact factor: 3.616

5.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

6.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Junín virus infection of human hematopoietic progenitors impairs in vitro proplatelet formation and platelet release via a bystander effect involving type I IFN signaling.

Authors:  Roberto G Pozner; Agustín E Ure; Carolina Jaquenod de Giusti; Lina P D'Atri; Joseph E Italiano; Oscar Torres; Victor Romanowski; Mirta Schattner; Ricardo M Gómez
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

8.  Early viral protein synthesis is necessary for NF-kappaB activation in modified vaccinia Ankara (MVA)-infected 293 T fibroblast cells.

Authors:  Stefani Martin; Joanna L Shisler
Journal:  Virology       Date:  2009-06-18       Impact factor: 3.616

9.  Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.

Authors:  James W Hodge; Jack Higgins; Jeffrey Schlom
Journal:  Vaccine       Date:  2009-05-29       Impact factor: 3.641

10.  Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Authors:  Zoe Waibler; Martina Anzaghe; Holger Ludwig; Shizuo Akira; Siegfried Weiss; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.